Non-small Cell Lung Cancer
Conditions
Brief summary
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage. Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint. Approximately 320 participants are estimated to be randomized into the study. Participants enrolled will be randomized to DZD9008 or platinum-based doublet chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without).
Interventions
DRUGsunvozertinib
orally, 300 mg, once daily until a treatment discontinuation criterion is met.
Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
Sponsors
Dizal Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged at least 18 years old (or per local regulatory/IRB requirement). 2. Histologically or cytologically confirmed diagnosis of non-squamous NSCLC, locally advanced (Stage IIIB and IIIC according to the 8th edition of the AJCC TNM staging criteria) or metastatic (Stage IV), not suitable for curative therapy. 3. Adequate tumor tissue available, for central laboratory confirmation of EGFR exon 20 insertion mutation 4. At least 1 measurable lesion per RECIST Version 1.1 5. Life expectancy ≥ 12 weeks 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 7. Adequate organ and hematologic function
Exclusion criteria
1. Prior treatment with any systemic anti-cancer therapy for locally advanced or metastatic NSCLC. 2. Spinal cord compression or leptomeningeal metastasis. 3. Concurrent EGFR mutations: exon 19 deletion, L858R, T790M, G719X, S768I, or L861Q. 4. History of stroke or intracranial hemorrhage within 6 months before randomization. 5. As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses (i.e., hemophilia and Von Willebrand disease).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) per RECIST 1.1 | Up to approximately 34 months after the first participant is randomized |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival | Up to approximately 34 months after the first participant is randomized |
Countries
Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Italy, Netherlands, Poland, Spain, Turkey (Türkiye), United States
Contacts
PRINCIPAL_INVESTIGATORCaicun Zhou
Shanghai Pulmonary Hospital, Shanghai, China
Outcome results
None listed